- Home
- FCN vs PCVX Comparison
FCN vs PCVX Comparison
Compare FCN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCN
- PCVX
- Stock Information
- Founded
- FCN 1982
- PCVX 2013
- Country
- FCN United States
- PCVX United States
- Employees
- FCN N/A
- PCVX N/A
- Industry
- FCN Professional Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- FCN Consumer Discretionary
- PCVX Health Care
- Exchange
- FCN Nasdaq
- PCVX Nasdaq
- Market Cap
- FCN 5.5B
- PCVX 4.4B
- IPO Year
- FCN 1996
- PCVX 2020
- Fundamental
- Price
- FCN $163.58
- PCVX $35.76
- Analyst Decision
- FCN Hold
- PCVX Strong Buy
- Analyst Count
- FCN 2
- PCVX 10
- Target Price
- FCN $175.50
- PCVX $136.50
- AVG Volume (30 Days)
- FCN 364.6K
- PCVX 1.5M
- Earning Date
- FCN 07-24-2025
- PCVX 08-05-2025
- Dividend Yield
- FCN N/A
- PCVX N/A
- EPS Growth
- FCN N/A
- PCVX N/A
- EPS
- FCN 7.32
- PCVX N/A
- Revenue
- FCN $3,668,381,000.00
- PCVX N/A
- Revenue This Year
- FCN $0.23
- PCVX N/A
- Revenue Next Year
- FCN $6.96
- PCVX N/A
- P/E Ratio
- FCN $22.41
- PCVX N/A
- Revenue Growth
- FCN 1.59
- PCVX N/A
- 52 Week Low
- FCN $151.75
- PCVX $27.66
- 52 Week High
- FCN $243.60
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- FCN 50.56
- PCVX 57.77
- Support Level
- FCN $159.54
- PCVX $31.79
- Resistance Level
- FCN $167.06
- PCVX $36.89
- Average True Range (ATR)
- FCN 2.41
- PCVX 1.51
- MACD
- FCN 0.39
- PCVX 0.37
- Stochastic Oscillator
- FCN 59.62
- PCVX 77.65
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.